P524: PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML (KB-LANRA 1001)

• E. M. Stein,
• A. Patel,
• L. C. Michaelis,
• G. Schiller,
• R. Swords,
• L. A. Carvajal,
• G. Bray,
• J. DiMartino,
• M. Y. Levy

Affiliations

E. M. Stein

1 Memorial Sloan Kettering Cancer Center, New York

A. Patel

2 The University of Chicago Medical Center, Chicago

L. C. Michaelis

3 Medical College of Wisconsin, Milwaukee

G. Schiller

4 University of California Los Angeles (UCLA), Los Angeles

R. Swords

5 Oregon Health and Science University, Portland

L. A. Carvajal

6 Kronos Bio, Inc., San Mateo

G. Bray

6 Kronos Bio, Inc., San Mateo

J. DiMartino

6 Kronos Bio, Inc., San Mateo

M. Y. Levy

7 Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, United States of America